Literature DB >> 1664062

Pharmacological and biochemical characteristics of partially purified GABAB receptor.

Y Ohmori1, K Kuriyama.   

Abstract

Pharmacological and biochemical characteristics of the partially purified gamma-aminobutyric acid (GABA)B receptor using baclofen affinity column chromatography have been examined. The Scatchard analysis of [3H]GABA binding to the purified GABAB receptor showed a linear relationship and the KD and Bmax values were 60 nM and 118 pmol/mg of protein, respectively. Although GTP and Mg2+ did not affect on the GABAB receptor binding, Ca2+ significantly increased [3H]GABA binding to the purified GABAB receptor in a dose-dependent manner and showed its maximum effect at 2 mM. The enhancement of the binding by Ca2+ was found to be due to the increase of Bmax by the Scatchard analysis. The treatments with pronase and trypsin significantly decreased the binding of [3H]GABA, but phospholipase A2 had no significant effect on the binding. In addition, treatment with glycosidases such as glycopeptidase A and beta-galactosidase significantly decreased the binding of [3H]GABA to the purified GABAB receptor. These results suggest that purification of the solubilized GABAB receptor by the affinity column chromatography may result in the functional uncoupling of GABAB receptor with GTP-binding protein. Furthermore, the present results suggest that cerebral GABAB receptor may be a glycoprotein and membrane phospholipids susceptible to phospholipase A2 treatment may not be involved in the exhibition of the binding activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1664062     DOI: 10.1007/bf00966099

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  24 in total

1.  Negative coupling of ?-aminobutyric acid (GABA)(B) receptor with phosphatidylinositol turnover in the brain.

Authors:  Y Ohmori; K Kuriyama
Journal:  Neurochem Int       Date:  1989       Impact factor: 3.921

2.  Solubilization and immunopurification of a somatostatin receptor from the human gastric tumoral cell line HGT-1.

Authors:  F Reyl-Desmars; S Le Roux; C Linard; F Benkouka; M J Lewin
Journal:  J Biol Chem       Date:  1989-11-05       Impact factor: 5.157

3.  Affinity chromatography of A1 adenosine receptors of rat brain membranes.

Authors:  H Nakata
Journal:  Mol Pharmacol       Date:  1989-06       Impact factor: 4.436

4.  Modulation of synaptic GABA receptor binding by membrane phospholipids: possible role of active oxygen radicals.

Authors:  Y Yoneda; K Kuriyama; M Takahashi
Journal:  Brain Res       Date:  1985-04-29       Impact factor: 3.252

5.  Solubilization and partial purification of GABAB receptor from bovine brain.

Authors:  Y Ohmori; K Kuriyama
Journal:  Biochem Biophys Res Commun       Date:  1990-10-15       Impact factor: 3.575

6.  2-Hydroxy-saclofen: an improved antagonist at central and peripheral GABAB receptors.

Authors:  D I Kerr; J Ong; G A Johnston; J Abbenante; R H Prager
Journal:  Neurosci Lett       Date:  1988-09-23       Impact factor: 3.046

7.  The D2-dopamine receptor of anterior pituitary is functionally associated with a pertussis toxin-sensitive guanine nucleotide binding protein.

Authors:  S E Senogles; J L Benovic; N Amlaiky; C Unson; G Milligan; R Vinitsky; A M Spiegel; M G Caron
Journal:  J Biol Chem       Date:  1987-04-05       Impact factor: 5.157

8.  gamma-aminobutyric acid B receptors are negatively coupled to adenylate cyclase in brain, and in the cerebellum these receptors may be associated with granule cells.

Authors:  W J Wojcik; N H Neff
Journal:  Mol Pharmacol       Date:  1984-01       Impact factor: 4.436

9.  3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain.

Authors:  D R Hill; N G Bowery
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

10.  Inhibition of GABAB receptor binding by guanyl nucleotides.

Authors:  D R Hill; N G Bowery; A L Hudson
Journal:  J Neurochem       Date:  1984-03       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.